That's right, most of the large pharma acquisitions that occurred in the 2022 Year was when a bio tech company showed good results around efficacy and safety during there phase 3 or combined phase 2/3 studies and not necessarily once the medicine got FDA approval.
Im predicting a buyout towards the latter part of the year, when incannex provides the market with the interim analysis on IHL 42x
IHL Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held